/주식/SNDX
SNDX

SNDX

USD

Syndax Pharmaceuticals Inc. Common Stock

$15.350+1.750 (12.868%)

실시간 가격

Healthcare
생명공학
미국

가격 차트

Loading Chart...

핵심 지표

시장 지표
기업 기본 정보
거래 통계

시장 지표

시가

$13.600

고가

$15.799

저가

$13.150

거래량

3.36M

기업 기본 정보

시가총액

1.3B

산업

생명공학

국가

United States

거래 통계

평균 거래량

2.67M

거래소

NMS

통화

USD

52주 범위

저가 $8.58현재가 $15.350고가 $22.5

관련 뉴스

Analyst Upgrades

UBS Maintains Buy on Syndax Pharmaceuticals, Raises Price Target to $38

UBS analyst David Dai maintains Syndax Pharmaceuticals with a Buy and raises the price target from $35 to $38.

더 보기
UBS Maintains Buy on Syndax Pharmaceuticals, Raises Price Target to $38
Analyst Upgrades

Barclays Maintains Overweight on Syndax Pharmaceuticals, Raises Price Target to $22

Barclays analyst Peter Lawson maintains Syndax Pharmaceuticals with a Overweight and raises the price target from $19 to $22.

더 보기
Barclays Maintains Overweight on Syndax Pharmaceuticals, Raises Price Target to $22
GlobeNewswire

Syndax Announces Compelling Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr) Data Accepted for Presentation at ASH 2025

– 12 revumenib and 11 axatilimab abstracts accepted, including 6 oral presentations, underscoring Syndax's leadership in menin inhibition and CSF-1R inhibition – – Revumenib abstracts showcase compelling results in

더 보기
Syndax Announces Compelling Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr) Data Accepted for Presentation at ASH 2025
GlobeNewswire

Syndax to Host ASH Investor Event in Person and via Webcast on December 8, 2025

NEW YORK, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that the Company will host an

더 보기
Syndax to Host ASH Investor Event in Person and via Webcast on December 8, 2025
GlobeNewswire

Syndax Announces Participation in November Investor Conferences

NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief

더 보기
Syndax Announces Participation in November Investor Conferences
GlobeNewswire

Syndax to Announce Third Quarter 2025 Financial Results and Host Conference Call and Webcast on November 3, 2025

NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will report its third

Analyst Upgrades

HC Wainwright & Co. Reiterates Buy on Syndax Pharmaceuticals, Maintains $40 Price Target

HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Syndax Pharmaceuticals with a Buy and maintains $40 price target.